Synergy Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development of drugs to treat gastrointestinal disorders and diseases in the United States. Its lead product candidate is Plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, which is in Phase II/III clinical trials to treat gastrointestinal disorders, primarily chronic constipation. The company also develops Plecanatide for the treatment of constipation-predominant-irritable bowel syndrome. In addition, it develops SP-333, a second generation GC-C receptor analog that is in pre-clinical development stage for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis and Crohn's disease. The company is headquartered in New York, New York.